RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. — Stella

Recruiting

Back to ALL, Adult trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

Chen Suning

Enrollment target

~124 participants

Started

February 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

15 Years – 65 Years

Last updated April 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov